OCT in Rare Chorioretinal Diseases
Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 7 Years to 100 Years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Subject-Level Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to give informed consent. 2. Inability to complete study tests within a 30 day period 3. Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant. 4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control). 5. Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible. 6. Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography. Study-Eye Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to maintain stable fixation for OCT imaging. 2. An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract) 3. Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal). 4. Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.
Study sites (1)
OR
- Casey Eye Institute, Oregon Health & Science University · Portland, OR 97239-3098Kevin Lathrop · Study contact · 503-494-8024 · lathropk@ohsu.eduDenny Romfh, OD · Study contact · 503-494-4351 · romfhd@ohsu.eduJohn Campbell, MD, MPH · Sub-investigatorAndreas Lauer, MD · Sub-investigatorMore trials in Portland